PharmaCyte Biotech
PMCB
PMCB
31 hedge funds and large institutions have $12M invested in PharmaCyte Biotech in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 9 increasing their positions, 10 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more ownership
Funds ownership: →
less funds holding
Funds holding: →
10% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 10
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
79% less call options, than puts
Call options by funds: $390K | Put options by funds: $1.85M
Holders
31
Holding in Top 10
2
Calls
$390K
Puts
$1.85M
Top Buyers
| 1 | +$2.11M | |
| 2 | +$1.25M | |
| 3 | +$480K | |
| 4 |
IEFM
IQ EQ Fund Management
Dublin 2,
Ireland
|
+$93K |
| 5 |
SC
Shay Capital
New York
|
+$79.1K |
Top Sellers
| 1 | -$1.18M | |
| 2 | -$149K | |
| 3 | -$72K | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$36.1K |
| 5 |
FIA
FNY Investment Advisers
New York
|
-$34K |